Tech Center 1700 • Art Units: 1634 1683 1797
This examiner grants 63% of resolved cases
Frank Wei Min Lu is an examiner in Art Unit 1634 of Tech Center 1700. Across 711 resolved cases, the examiner maintains an allowance rate of 62.7 percent. This rate suggests a fair probability of success for applicants, with more than six out of ten cases resulting in a grant. Practitioners can use the 62.7 percent figure to benchmark their prosecution strategy in this unit.
The interview lift is 67.7 percent. This exceptionally high lift indicates that interviews are a vital component of a successful prosecution strategy. Practitioners should leverage the 67.7 percent lift to overcome rejections, as it represents one of the most significant benefits of verbal engagement seen in the data. The high lift suggests that direct communication is highly effective at resolving the examiner's concerns.
The median days to allowance is 1502. This is a long timeline, suggesting that the path to a grant often takes over four years. Given the 62.7 percent allowance rate and the 67.7 percent interview lift, persistent engagement and early interviews may be necessary to navigate the 1502-day median pendency. These metrics provide a comprehensive view of the time and tactics required for success.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18132298 | METHODS AND COMPOSITIONS FOR LIGATION AND SAMPLE ANALYSIS | Final Rejection | 10x Genomics, Inc. |
| 17812075 | METHODS FOR SAMPLE TRANSFER FOR IN SITU ANALYSIS | Non-Final OA | 10x Genomics, Inc. |
| 17911633 | COMPOSITIONS AND METHODS OF TREATING GLIOMA | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18068858 | ANTISENSE FINGERLOOP DNAS AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 19363300 | Methods for Adding Adapters to Nucleic Acids and Compositions for Practicing the Same | Final Rejection | Takara Bio USA, Inc. |
| 17980848 | Methods for Adding Adapters to Nucleic Acids and Compositions for Practicing the Same | Final Rejection | Takara Bio USA, Inc. |
| 18249597 | A SCREENING PLATFORM FOR ADAR-RECRUITING GUIDE RNAS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 19344246 | METHODS FOR THREE-DIMENSIONAL NUCLEIC ACID SEQUENCING | Non-Final OA | Singular Genomics Systems Inc. |
| 18069990 | STRAND DISPLACING SEQUENCING ENZYMES | Non-Final OA | Singular Genomics Systems, Inc. |
| 17938329 | METHODS FOR IN SITU PROTEOMICS | Non-Final OA | Singular Genomics Systems, Inc. |
| 18074369 | METHOD OF MAPPING SPATIAL DISTRIBUTIONS OF CELLULAR COMPONENTS | Final Rejection | CALIFORNIA INSTITUTE OF TECHNOLOGY |
| 17821449 | MEASUREMENT OF PROTEIN EXPRESSION USING REAGENTS WITH BARCODED OLIGONUCLEOTIDE SEQUENCES | Non-Final OA | Becton, Dickinson and Company |
| 17865159 | Set of Oligonucleotide Probes as Well as Methods and Uses Thereto | Final Rejection | Roche Molecular Systems, Inc. |
| 18015627 | SYSTEMS AND METHODS FOR CELL CAPTURE, BIOMARKER DETECTION, AND CONTACT-FREE CELL LYSIS | Final Rejection | Trustees of Dartmouth College |
| 17871702 | PROGRAMMABLE ENZYME-ASSISTED SELECTIVE EXPONENTIAL AMPLIFICATION FOR SENSITIVE DETECTION OF RARE MUTANT ALLELES | Non-Final OA | The Trustees of the University of Pennsylvania |
| 16849549 | METHODS AND COMPOSITIONS FOR BIOSENSING | Final Rejection | The University of North Carolina at Charlotte |
| 15534577 | DETECTION OF TARGET NUCLEIC ACID SEQUENCES USING DIFFERENT DETECTION TEMPERATURES AND REFERENCE VALUES | Non-Final OA | SEEGENE, INC. |
| 17917826 | RESPONSIVE, CATALYTIC NUCLEIC NANOSTRUCTURES | Final Rejection | Agency for Science, Technology and Research |
| 17344535 | METHODS FOR PURIFICATION OF MESSENGER RNA | Non-Final OA | Translate Bio, Inc. |
| 18800497 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Non-Final OA | Sequenom, Inc. |
| 18059370 | METHODS OF CAPTURING CELL-FREE METHYLATED DNA AND USES OF SAME | Non-Final OA | Sinai Health System |
| 17839177 | PROCESSIVE ENZYME MOLECULAR ELECTRONIC SENSORS FOR DNA DATA STORAGE | Final Rejection | Roswell Biotechnologies, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy